Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study

Table 2 IVIM parameters of responders and non-responders

	ADC (10⁻³ mm²/s)		DC (10⁻³ mm²/s)		D* (10⁻³ mm²/s)		PF
	Responder	Non-responder	Responder	Non-responder	Responder	Non-responder	Responder	Non-responder
Baseline	1.06 ± 0.21	0.85 ± 0.04	1.04 ± 0.23	0.78 ± 0.06	228 ± 392	317 ± 274	0.20 ± 0.28	0.10 ± 0.08
1 week	0.98 ± 0.25	1.00 ± 0.05	0.99 ± 0.38	0.94 ± 0.20	452 ± 376	657 ± 555	0.06 ± 0.04	0.06 ± 0.04
2 weeks	0.93 ± 0.16	0.88 ± 0.33	0.90 ± 0.25	0.84 ± 0.32	470 ± 441	676 ± 272	0.12 ± 0.11	0.07 ± 0.08
4 weeks	0.84 ± 0.11	0.92 ± 0.33	0.80 ± 0.08	0.83 ± 0.23	321 ± 389	323 ± 276	0.08 ± 0.06	0.10 ± 0.12

ADC apparent diffusion coefficient, DC true diffusion coefficient, D* pseudo-diffusion coefficient, PF perfusion fraction

ISSN: 1470-7330